ManagedCareEye.com Presents: Managed Care Consensus Recommendations to Facilitate Equitable Access and Optimal Outcomes for Retinal Diseases

• Release Date: July 31, 2024
• Expiration Date: July 31, 2026
• Estimated Time to Complete Activity: 1.0 hour
• Compatible with all modern browsers and mobile devices

Expert Faculty Presenters

Mark Barakat, MD Retina Macula Institute of Arizona Click here for biography Justin Weiss, PharmD, MBA VP, Pharmacy Operations and Compliance Cambia Health Solutions Click here for biography

Target Audience

This activity is intended for managed care pharmacy directors, registered nurses, clinical pharmacists, quality directors and medical directors.

Program Overview

Retinal diseases result in remarkable morbidity among plan members, including vision loss and blindness. Furthermore, disparities exist in incidence and outcomes among those affected by social determinants of health (SDOH). This activity, presented by ManagedCareEye.com, will educate managed care and payer professionals regarding best practices in enhancing retinal disease care equity and access.

Educational Objectives 
After completing this activity, the participant should be better able to:

• Identify current disparities in the care of retinal diseases
• Outline the importance anti-VEGF therapies with extended duration of effect for patients impacted by SDOH
• Describe means by which to address the impact of SDOH via utilization management programs

DISCLOSURE OF UNLABELED USE
This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
This program is provided by Impact Education, LLC and is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

FEE INFORMATION
There is no fee for this activity.